Welcome to our dedicated page for Zomedica news (Ticker: ZOMDF), a resource for investors and traders seeking the latest updates and insights on Zomedica stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zomedica's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zomedica's position in the market.
Zomedica (OTCQB:ZOMDF) announces its upcoming Fourth Friday at Four webinar on July 25, 2025, focusing on their Assisi product line of targeted Pulsed Electromagnetic Field (tPEMF) therapy devices. The webinar will showcase their drug-free solutions including the Assisi Loop®, Assisi Loop Lounge®, and Calmer Canine® products.
The session will feature insights into tPEMF technology, clinical outcomes, and real-world applications in veterinary care. Led by Nicole Westfall, Senior VP of Marketing, and Mialisa Gluckert, Senior Director of Assisi Commercialization, the webinar will demonstrate how these non-invasive treatments are revolutionizing pain and inflammation management in companion animals.
Zomedica (OTCQB:ZOMDF) has announced a strategic sponsorship agreement between its PulseVet shock wave device and the World Equestrian Center - Ocala (WEC), establishing PulseVet as the official shock wave therapy provider at the venue. The partnership includes comprehensive brand visibility through arena signage, digital promotions, and features in WEC publications.
The collaboration aims to enhance veterinary care for elite equine athletes by providing non-invasive shock wave therapy for musculoskeletal injuries. The agreement includes on-site educational resources, promotional materials, and hospitality privileges during WEC events, including discounted lodging and VIP access.
Zomedica (OTCQB:ZOMDF) has been granted a new U.S. Patent (No. 12,299,917 B2) for its TRUVIEW microscope, specifically covering Methods and Systems for Slide Imaging Calibration. The patent strengthens the company's intellectual property portfolio, which now comprises 77 U.S. patents, 144 international patents, 33 U.S. trademarks, and 107 foreign trademarks.
Bill Campbell, VP of Imaging Systems and TRUVIEW's inventor, emphasized the patent's significance in validating their focusing system innovation. CEO Larry Heaton highlighted how this protection enables continued investment in market expansion while maintaining product uniqueness.
Zomedica (OTCQB:ZOMDF) has announced significant enhancements to its equine insulin assay for the TRUFORMA Diagnostic Platform. The update features an extended dynamic range, increased by 60% from its previous version, and introduces an innovative automatic sample dilution function. This advancement allows veterinarians to measure insulin levels at the highest ranges without additional steps or increased time-to-result.
The new automatic dilution feature eliminates the need for manual dilution protocols for samples exceeding 250 µU/mL, streamlining the testing process. The enhancement maintains test consistency while freeing staff from additional tasks. This development positions TRUFORMA as having the widest dynamic range available both at Point of Care and compared to Reference Labs.
Zomedica Corp. (OTCQB:ZOMDF) has announced the launch of a new monthly webinar series called "Fourth Friday at Four" starting May 23rd, 2025. The series aims to showcase the company's innovative veterinary health products and technologies to investors, veterinarians, and industry partners.
The webinars will highlight Zomedica's product portfolio including the PulseVet® Shock Wave system for musculoskeletal healing, Assisi Loop® and Calmer Canine for pain management and anxiety, TRUFORMA® diagnostic platform, TRUVIEW® Digital Cytology System, VETGuardian® monitoring system, and VETIGEL® hemostatic gel. CEO Larry Heaton emphasized that the series will focus on building a community of professionals while providing insights into the company's technologies and growth strategy.
- Therapeutics revenue reached $5.9M (+8% YoY) - Consumables revenue grew to $4.5M (+13% YoY) - International sales increased 32% YoY - Cash position of $64.6M as of March 31, 2025
However, the company recorded a significant net loss of $63.8M, primarily due to a non-cash impairment charge of $55.8M triggered by market capitalization decline. Excluding this charge, adjusted operating expenses were $13.2M, down 9% YoY. The diagnostics segment saw a 25% revenue decline to $0.6M, mainly due to non-recurring initial distribution orders from the previous year.
Zomedica (OTCQB:ZOMDF) has launched the Equine Asthma Clinical Registry, a groundbreaking program utilizing PulseVet® shock wave therapy as a non-invasive, drug-free treatment for equine asthma. The initiative aims to gather real-world clinical evidence on the effectiveness of electrohydraulic extracorporeal shock wave therapy (ESWT) in treating respiratory conditions in horses.
Initial studies show promising results, with 58 horses completing treatment without adverse events. The registry allows veterinary clinics to enroll up to 20 horses, requiring three scheduled visits over 4-6 weeks. Equine asthma affects approximately 15% of horses over age seven, impacting their performance and quality of life. The program offers participating clinics product credits while contributing to vital research in advancing equine respiratory care.
Zomedica Corp. (ZOMDF), a veterinary health company specializing in point-of-care diagnostic and therapeutic products for equine and companion animals, has scheduled its Q1 2025 earnings conference call for Thursday, May 15, 2025, at 4:30 p.m. ET. The call will cover operational and financial highlights for the quarter ended March 31, 2025, followed by a Q&A session.
Participants can join via phone at +1-800-717-1738 (U.S. Toll-Free) or +1-646-307-1865 (International). A replay will be available until May 29, 2025, accessible by dialing +1-844-512-2921 (U.S.) or +1-412-317-6671 (International) with pin 1148151.
Zomedica (OTCQB:ZOMDF) reported strong financial results for Q4 and full-year 2024. The company achieved record Q4 revenue of $7.9 million (8% growth) and full-year revenue of $27.3 million (8% increase from 2023). Notable highlights include:
The Diagnostics segment showed exceptional growth of 109% year-over-year, driven by TRUFORMA® and VETGuardian® product lines. The company maintained a robust gross margin of 70% and ended the year with $71.4 million in liquidity.
Despite the revenue growth, Zomedica reported a net loss of $7.2 million for Q4 and $47.0 million for the full year. The company's operating expenses increased to $70.1 million in 2024, up 16% from 2023. Looking ahead to 2025, Zomedica plans to focus on the equine market through new product launches and distribution agreements, including Vetigel® hemostatic gel.
FAQ
What is the current stock price of Zomedica (ZOMDF)?
What is the market cap of Zomedica (ZOMDF)?
